HUTCHMED (China) Net Cash Flow 2014-2024 | HCM

HUTCHMED (China) net cash flow from 2014 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.

HUTCHMED (China) Net Cash Flow 2014-2024 | HCM

HUTCHMED (China) net cash flow from 2014 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$226.4B
Amgen (AMGN)$166.3B
Gilead Sciences (GILD)$141.3B
Vertex Pharmaceuticals (VRTX)$122.5B
Bristol Myers Squibb (BMY)$99.7B
CSL (CSLLY)$85.2B
GSK (GSK)$77.9B
Regeneron Pharmaceuticals (REGN)$61.8B
Alnylam Pharmaceuticals (ALNY)$42.5B
Argenex SE (ARGX)$35.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.2B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.2B
Illumina (ILMN)$16.6B
Genmab (GNMSF)$14.9B
Genmab (GMAB)$14.7B
Incyte (INCY)$13.7B
Moderna (MRNA)$13.4B
Exelixis (EXEL)$12.4B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.7B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B